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physicians were sent prior to the patient letters. Diabetic
patients absent of statin treatment in a prior 120-day period
were identiﬁed. Continuous eligibility was required for the
evaluation and only patients over 17 years of age were
included. Patients were observed for adding a statin during a
120-day follow-up period. Controls were identiﬁed from four
other plans with similar characteristics. One-to-one case-
control matching and t-test were performed to evaluate the
effect of the interventions. Regression analyses were performed
to determine the predictors of intervention responsiveness.
RESULTS: Mean age for patients in the program was approxi-
mately 55 years. There were 760 unique patients in both the
patient and physician intervention components. Overall, 170
(22.4%) and 112 (11.0%) patients added a statin in the case
versus control group (difference 11.4%, p < 0.0001). Speciﬁ-
cally, among the physician intervention component there were
17.8% and 11.6% of cases versus controls who added a statin
(difference = 6.22%, p < 0.05). Among the patient intervention
component there were 12.3% and 8.6% cases versus controls
who added a statin (difference 3.84%, p < 0.05). Signiﬁcant
positive predictors of adding a statin include presence of car-
diovascular disease, females, and higher comorbidities. CON-
CLUSION: Educational letter-based programs that are directed
to physicians and patients are effective in promoting the use of
statin therapy among diabetics.
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THE ASSESSING CARDIOVASCULARTARGETS (ACT ’07)
PROGRAM: PRELIMINARY RESULTS FROM A PRACTICE
REFLECTIVE ASSESSMENT ACROSS CANADA
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OBJECTIVE: To examine patients’ level of cardiovascular risk
in community based clinical practice and assess whether treat-
ment targets as speciﬁed in Canadian clinical guidelines
(hypertension—2007, dyslipidemia—2006, diabetes—2003,
metabolic syndrome—2006) are met. METHODS: A conve-
nience sample of more than 375 general practitioners recruited
from across Canada participated between September and Decem-
ber 2007. Case report forms were completed for at least 20
patients during normally scheduled ofﬁce visits. Current survey
results were compared to a similar survey of 450 general practi-
tioners and 17,188 patients conducted in January to April 2006
that used the 2003 dyslipidemia, 2003 diabetes, & 2005 hyper-
tension guideline targets to assess whether treatment targets were
met. RESULTS: A total of 1722 patients analyzed to date of
which 98% were taking lipid-lowering drugs. Approximately
14,000 patients’ data will be available upon study completion.
Demographics: 57% male, 40% 65 years or older, 53% 45–64
years. CV risk factors identiﬁed: 68% hypertension, 38% diabe-
tes, 26% family history premature CAD, 24% previous history
of MI, stroke, or PAD, 25% current or recent smoker, 9%
evidence of hyperdyslipidemia. Fifty-four percent of cohort had
three or more risk factors. Physician assessed CV risk level: 59%
high, 24% moderate, 18% low. Forty percent of patients met the
criteria for metabolic syndrome. Patients NOT at guideline
targets 2007 survey vs. 2006 survey: hypertension 22% vs. 26%,
LDL-C 47% vs. 34%, TC : HDL-C 35% vs. 31%, triglycerides
42% vs. 51%, FBG > 6.2 mmol. 34% vs. 44%, waist circumfer-
ence 55% vs. 55%. CONCLUSION: Preliminary aggregate data
shows that despite drug treatment many patients are still not at
lipid or blood pressure target levels. Community practice physi-
cians in this survey prescribe lipid-lowering drugs to predomi-
nantly high (59%) and moderate (24%) CV risk patients.
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OBJECTIVE: The environment of caring for acute stroke
patients impacts the outcome of the process. The aim of the study
was to explore the present institutional conditions of acute stroke
units and to compare these to the Hungarian national standards.
METHODS: A cross sectional study design was used to explore
the present conditions for acute stroke nursing (nurse stafﬁng,
skill mix, shift patterns, physical environment, etc.) in 11 insti-
tutions representing all regions of Hungary. The collected data
were compared to the professional standards lied in the govern-
ment decree. The data were collected in the beginning of 2005.
The data analysis was done with Chi-square and ANOVA
method using SPSS 11.0. RESULTS: The examined institutions
represent 19% (658) of active neurological beds in Hungary. The
nursing posts were not ﬁlled in 13% of the 11 units, furthermore
the total number of nursing posts were under the minimum
recommended standards with 17%. A total of 81% (219) of the
ﬁlled nursing posts are staffed with qualiﬁed registered nurses,
out of them 5% has a degree. In three institutions degree nurses
are not available at al. 80% of the nurses are between 21–45
years. The average nurse-patient ratio: 2.4:1 (lowest: 1.8, the
more: 3.6). In 10 out of 11 institutions have ISO 9001 QA
accreditation. The tools for helping nurses’ work are not enough
and correlating with lower qualiﬁcation levels signiﬁcantly
(p < 0.01). CONCLUSION: The nursing shortage is a serious
problem in stroke units (30%). Therefore, nursing can not meet
the criteria lied in the government decree and in the ISO 9001
system. Although the majority of the nursing staff are qualiﬁed
not all department employs degree nurses who could develop the
professional nursing.
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OBJECTIVE: To examine the relationship between the excessive
cost and quality of care across US hospitals for Medicare patients
undergoing lower extremity by pass surgery. METHODS: We
examined outlier payments in patients undergoing lower extrem-
ity bypass surgery (n = 43,886) using National Medicare claims
database. Using multiple logistic regression we explored the rela-
tionship between hospital outlier payments and hospital quality
as reﬂected by risk-adjusted mortality rates. RESULTS: The pro-
portion of patient associated with outlier payments was 10%.
Total Medicare outlier payments for lower-extremity bypass
graft was $78,921,669 averaging $18,214 per patient. There was
a negative correlation between risk-adjusted mortality rates and
outlier payments. Proportion of systematic variation in hospital
outlier payment rates explained by hospital factors explained
7.8% of in-between variation of outlier rates in lower extremity
bypass. CONCLUSION: There exist negative relationship
between quality and excessive cost across the hospitals. However,
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only small variation of the excessive cost distribution can be
explained by quality.
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OBJECTIVE: To evaluate the impact of guidelines for treatment
and prophylaxis of VTE on appropriateness of anticoagulant
therapy, JCAHO performance measures, adverse drug outcomes,
and total cost of therapy. METHODS: We conducted a multi-
hospital ‘pre-post’ guideline intervention study. Guidelines for
VTE treatment and prophylaxis were developed and imple-
mented in the participating hospitals. Retrospective chart review
was used to collect patient data during the pre and post periods.
RESULTS: The number of participating hospitals and total
patient cases submitted by the hospitals were 23 and 617, respec-
tively in the pre-guideline (PRG) phase and 13 and 338, respec-
tively in the post-guideline phase (POG). The appropriateness of
prescribing (as measured by the dose, duration, and the type of
anticoagulant used) increased by 7% (PRG 77%, POG 84%).
JCAHO performance measures for 1) percentage of VTE patients
receiving education; 2) percentage of patients with reduced
LMWH dosage in compromised renal failure; 3) percentage of
patients with normal INR; 4) percentage of patients with objec-
tive conﬁrmation of clinically suspected VTE; 5) percentage of
unfractionated heparin (UFH) managed by nomogram/protocol;
and 6) percentage of patients with anticoagulation overlap of
parenteral and warfarin therapy, increased by 20%,17%, 13%,
9%, 6%, and 1%, respectively. JCAHO measures for 1) VTE
treatment for discharged patients with active cancer, and 2) plate-
let count monitoring for patients with VTE receiving UFH,
decreased by 2% and 11%, respectively. The proportion of
patients experiencing at least one anticoagulant related adverse
drug outcome decreased by 0.5% and rates of major bleeding
decreased by 1% in POG. On average, the total cost of therapy
(cost of major/minor bleeding, DVT, PE and drugs costs)
decreased by $105 per patient in POG.
CONCLUSION: Implementation of VTE treatment and pro-
phylaxis guidelines improved appropriateness of anticoagulant
therapy in the participating hospitals resulting in improved out-
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OBJECTIVE: Numerous clinical outcomes trials have demon-
strated the beneﬁts of achieving glycemic goals in patients with
type 2 diabetes (T2D). In controlled clinical trials, the incretin
mimetic exenatide improved glycemic control in patients with
T2D; 34% to 46%of patients achieved A1C7%andmeanA1C
change from baseline was -0.8% to -0.9% (baseline A1Cs: 8.2%
to 8.7%). To investigate the effects of exenatide in clinical practice,
this retrospective cohort study used a large, US commercial health
plan claims database to describe baseline characteristics, comor-
bidities, concomitant therapies, and clinical effectiveness in
patients initiated on exenatide. METHODS: A total of 4936
patients were identiﬁed having a new prescription claim for
exenatide between May 1, 2005 and June 30, 2006 (ﬁrst
claim = index date), with 12 months of pre- and post-index
eligibility, and 18 years old. RESULTS: Mean (SD) age was
53.7  10.2 years (11.7% 65 y; 52% female). The 12-month
mean (SE) medication possession ratio (MPR = days of supply/
365 days) in patients with >1 prescription claim was 66  30%.
Most patients analyzed (94%)were treated with at least one other
antidiabetic medication at initiation (100 d pre-index to 15 d
post-index); 25% with one drug, 35% with two drugs, and 34%
with3 drugs. The mean number of antidiabetic drugs (including
exenatide) per patient was similar at initiation (3.08) and post-
index (3.05). Clinical effectiveness was measured in all patients
with an A1C >7.0% at baseline (100 d pre-index) and having
both baseline and post-index (60–365 d) A1C data available
(n = 201; mean baseline A1C = 8.9  1.5%). In this cohort, 31%
achieved A1C 7% in the post-index period and mean A1C
change from baseline was -0.8%. CONCLUSION: The mean
change in A1C and percentage of patients achieving A1C7% in
this real-world analysis mirrored results of controlled clinical
trials. Furthermore, glycemic improvement was achieved without
a further increase in concomitant antidiabetic drugs.
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OBJECTIVE: To study dosing frequency of metformin in relation
to HbA1c-goal attainment in daily practice. METHODS: Data
for this nested case-control study were obtained from the
PHARMO Record Linkage System, including among others
linked drug-dispensing and clinical-laboratory records of
approximately three million individuals in deﬁned areas of The
Netherlands. The study cohort included new users of oral
glucose-lowering drugs (OGLD) between 1999–2005, with a
baseline HbA1c 7% and consecutive HbA1c-measurements
within 18 months. Cases attained HbA1c-goal (HbA1c <7%)
within 18 months. Controls did not attain HbA1c-goal. Compli-
ant cases and controls on metformin monotherapy were included
in the analyses. Dosing frequency was dichotomized into once-
daily and twice-daily or more. In the multivariate analysis we
considered OGLD-dose, baseline HbA1c, prescriber and number
of HbA1c-measurements. RESULTS: The study cohort included
3107 new OGLD-users. The analyses included 753 cases and 477
controls using metformin. Dosing twice-daily or more was asso-
ciated with a 71% higher probability of attaining goal (OR 1.71
(95%CI 1.31–2.24)) compared to once-daily dosing, after adjust-
ment for baseline HbA1c and prescriber. We could not distin-
guish between the effect of dose and dosing frequency as these
were closely related. Statistical testing in the analyses stratiﬁed by
dose was prohibited by small numbers. CONCLUSION: About
40% of compliant metformin users were not at goal because of
dosing problems. A strong correlation between total daily dose
and dosing frequency did, however, not permit to identify one of
these dosing items as most important attribute.
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